NextPharma adds prefilled syringe capability in Belgium
Categories | Finance | Manufacturing | Equipment | Heating and Cooling | Material Transfer | Aseptic Systems | Packaging | Packaging Machinery | Filling Machinery | Lyophilisation |
NextPharma is adding a prefilled syringe capability at its Sterile Product Development Centre (SPDC) in Braine-l’Alleud, Belgium to meet customer demand for formulation development and manufacturing of pre-filled syringes containing both cytotoxic and non-cytotoxic products.
The SPDC will be equipped with semi-automatic syringe fillers with automatic stoppering units under vacuum in both the cytotoxic and non-cytotoxic units. These fillers are being configured to fill product aseptically in quantities typically used in Phase I and Phase II clinical trials. The first syringe filler is planned to be in operation in the first quarter of 2011.
The SPDC supports customers' development projects from pre-formulation and formulation through to investigational medicinal product manufacturing with lyophilisation for Phase I to Phase II clinical trials with scale-up capability to Phase III and commercial scale in NextPharma’s commercial manufacturing facility on the same site.
NextPharma has recently been acquired by Sun European Partners with a view to leveraging NextPharma’s strong track record, reputation and state of the art facilities, to grow the business both organically and by acquisition.
Subscribe now to Cleanroom Technology to get unrestricted online access to our exclusive content and receive our high quality magazine every month.
